Results of continuous hyperfractionated radiotherapy in treatment of non-small cell lung cancer

The purpose of this investigation was to evaluate feasibility, safety and efficacy of radiotherapy (RT) and chemoradiotherapy of inoperable non-small-cell lung cancer (NSCLC). Time to death and side effects were evaluated. From 2001 to 2005, a total of 96 patients with inoperable NSCLC stage IIB-IIIB were treated with continuous hyperfractionated radiotherapy at MRRC RAMS. Daily doses were 1 + 1,5Gy. Irradiation was provided 5 times per week. Depending on performance status and lung function, radiation doses were 60-70 Gy. Local control rate was 53,9 % 2 months after completion of radiotherapy. The median overall survival duration was 12 months and 3-year overall survival was 19 %. The respective rates were 17 months and 37,5 % in patients who received chemoradiotherapy. The treatment was well tolerated and the rate of side effects was low. Grade 3 pneumonitis was observed in 2,1 % of cases and grade 3 pericarditis in 4,2 % of cases